Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-002736.pdf
0001415889-22-002736.rtf
0001415889-22-002736.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-002737.pdf
0001415889-22-002737.rtf
0001415889-22-002737.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-002738.pdf
0001415889-22-002738.rtf
0001415889-22-002738.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-002740.pdf
0001415889-22-002740.rtf
0001415889-22-002740.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-002754.pdf
0001415889-22-002754.rtf
0001415889-22-002754.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-002653.pdf
0001415889-22-002653.rtf
0001415889-22-002653.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-002434.pdf
0001415889-22-002434.rtf
0001415889-22-002434.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-002432.pdf
0001415889-22-002432.rtf
0001415889-22-002432.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-002431.pdf
0001415889-22-002431.rtf
0001415889-22-002431.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-002449.pdf
0001415889-22-002449.rtf
0001415889-22-002449.xls